A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2)
Hidradenitis Suppurativa (HS)
About this trial
This is an interventional treatment trial for Hidradenitis Suppurativa (HS) focused on measuring Hidradenitis Suppurativa, HS, INCB054707, Povorcitinib, Acne inversa, Hidradenitis
Eligibility Criteria
Inclusion Criteria: Male and female participants ≥ 18 years of age. Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit. HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits. Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits. History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for HS) Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period. Willingness to avoid pregnancy or fathering children. Other inclusion criteria apply. Exclusion Criteria: Draining tunnel count of > 20 at Screening or Baseline visits. Women who are pregnant (or who are considering pregnancy) or breastfeeding. Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies. Evidence of infection with TB, HBV, HCV or HIV. History of failure to JAK inhibitor treatment of any inflammatory disease. Laboratory values outside of the protocol-defined ranges. Other exclusion criteria apply.
Sites / Locations
- Investigative Site US214Recruiting
- Investigative Site US223Recruiting
- Investigative Site US226Recruiting
- Investigative Site US222Recruiting
- Investigative Site US233
- Investigative Site US228Recruiting
- Investigative Site US227Recruiting
- Investigative Site US204Recruiting
- Investigative Site US200Recruiting
- Investigative Site US201Recruiting
- Investigative Site US220Recruiting
- Investigative Site US206Recruiting
- Investigative Site US209Recruiting
- Investigative Site US207Recruiting
- Investigative Site US229Recruiting
- Investigative Site US224
- Investigative Site US208Recruiting
- Investigative Site US225
- Investigative Site US221Recruiting
- Investigative Site US213Recruiting
- Investigative Site US217Recruiting
- Investigative Site US212Recruiting
- Investigative Site US230Recruiting
- Investigative Site US202Recruiting
- Investigative Site US210Recruiting
- Investigative Site US205Recruiting
- Investigative Site US215Recruiting
- Investigative Site US203Recruiting
- Investigative Site US232
- Investigative Site US218Recruiting
- Investigative Site AU205Recruiting
- Investigative Site AU203Recruiting
- Investigative Site AU206
- Investigative Site AU207
- Investigative Site BG203Recruiting
- Investigative Site BG202Recruiting
- Investigative Site BG200Recruiting
- Investigative Site BG204Recruiting
- Investigative Site BG201Recruiting
- Investigative Site CA202Recruiting
- Investigative Site CA204Recruiting
- Investigative Site CA200Recruiting
- Investigative Site CA205Recruiting
- Investigative Site CA207Recruiting
- Investigative Site CA206Recruiting
- Investigative Site CA203Recruiting
- Investigative Site DK201
- Investigative Site DK200
- Investigative Site FR200Recruiting
- Investigative Site FR205Recruiting
- Investigative Site FR204Recruiting
- Investigative Site FR203Recruiting
- Investigative Site FR206
- Investigative Site FR201Recruiting
- Investigative Site DE203
- Investigative Site DE208Recruiting
- Investigative Site DE200Recruiting
- Investigative Site DE204Recruiting
- Investigative Site DE206Recruiting
- Investigative Site IT200Recruiting
- Investigative Site IT204Recruiting
- Investigative Site IT207Recruiting
- Investigative Site IT202Recruiting
- Investigative Site IT206Recruiting
- Investigative Site IT205Recruiting
- Investigative Site PL203Recruiting
- Investigative Site PL200Recruiting
- Investigative Site PL201Recruiting
- Investigative Site PL202Recruiting
- Investigative Site ES203Recruiting
- Investigative Site ES202
- Investigative Site ES204Recruiting
- Investigative Site ES205Recruiting
- Investigative Site ES200Recruiting
- Investigative Site GB202
- Investigative Site GB204
- Investigative Site GB203
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Povorcitinib Dose A
Povorcitinib Dose B
Placebo
Participants will receive Povorcitinib Dose A for 54 weeks.
Participants will receive Povorcitinib Dose B for 54 weeks.
Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.